1. Think of it as the early-stage R&D pipeline of a large pharmaceutical company like Merck or Pfizer, but operating as an independent entity and still years away from bringing any drugs to market.

2. Like a nascent Regeneron, focused on discovering a wide range of new therapeutic compounds across diverse disease areas, but without any blockbuster drugs yet.

• TNX-1500: A humanized monoclonal antibody for preventing organ transplant rejection and treating autoimmune diseases.
• TNX-2900: A treatment for Prader-Willi syndrome.
• TNX-801: A vaccine to prevent smallpox and monkeypox.
• TNX-1840 and TNX-1850: Live virus vaccines based on its recombinant pox vaccine (RPV) platform for COVID-19.
• TNX-3500: A small molecule antiviral drug to treat acute COVID-19.
• TNX-102 SL: A small molecule drug to treat Long COVID and for the management of fibromyalgia.
• TNX-1900: A product in development for the prevention of migraine headache.
• TNX-1300: A biologic designed to treat cocaine intoxication.

Tonix Pharmaceuticals Holding Corp. (TNXP) is a clinical-stage biopharmaceutical company focused on research, development, and licensing of therapeutic and diagnostic product candidates. Based on the provided description, the company does not currently have any approved products on the market that generate commercial sales. Therefore, Tonix Pharmaceuticals Holding Corp. does not have major commercial customers in the traditional sense of selling products to other companies or directly to individuals.

Its primary activities involve advancing its drug candidates through clinical trials and potentially engaging in future licensing agreements with larger pharmaceutical companies, or securing funding from investors, which are not considered "customers" in the context of purchasing products or services from the company.

Seth Lederman, MD Co-Founder, CEO & Chairman

Dr. Lederman is a physician, scientist, and entrepreneur, and the founder of Tonix Pharmaceuticals. Prior to Tonix, he founded Targent Pharmaceuticals, which developed late-stage oncology drugs. Targent's assets, including levoleucovorin (marketed as Fusilev®), were later acquired by Spectrum Pharmaceuticals. For two decades, Dr. Lederman also served as an Associate Professor at Columbia University, where he directed basic science research in molecular immunology, infectious diseases, and the development of therapeutics for autoimmune diseases. He also served as an attending physician at the Edward Daniels Arthritis and Autoimmunity Clinic at Columbia Presbyterian Hospital.

Bradley Saenger, CPA Chief Financial Officer

Mr. Saenger joined Tonix Pharmaceuticals in May 2014 and currently serves as the Chief Financial Officer. He has over 10 years of experience in large publicly traded companies and an additional 10 years in public accounting. Prior to Tonix, Mr. Saenger worked as a consultant for Shire Pharmaceuticals and held leadership positions as a Director of Accounting at Vertex Pharmaceuticals, Inc., and a Manager of Corporate Accounting and Consolidations at Alere Inc. He also worked for PricewaterhouseCoopers LLP.

Jessica Morris Chief Operating Officer

Ms. Morris joined Tonix Pharmaceuticals in September 2013 and became Chief Operating Officer in January 2018. She has extensive experience in drug development, finance, and investing at both private and publicly traded companies. Before joining Tonix, Ms. Morris was a Vice President at Zhong Rong Group, a family office, and worked at American Capital, a publicly traded private equity firm. She also worked in an investment capacity at Calvert Street Capital Partners, a private equity firm, and Silicon Valley Bank, and began her career as an investment banking financial analyst at Deutsche Bank.

Siobhan Fogarty, BSc, MSc(QP) Chief Technical Officer

Ms. Fogarty joined Tonix in 2016 and was promoted to Chief Technical Officer in February 2025. She has over 25 years of experience in the development and manufacture of various dosage forms for small and large molecules at several life science companies. Ms. Fogarty started her career as a formulation scientist at Elan Corporation, where she gained experience in drug delivery and took products from concept to commercial manufacture. She also worked at Glaxo Wellcome (now GlaxoSmithKline) as a manufacturing strategist and established European product development sites for Fuisz Technologies and Biovail Corporation. Subsequently, she started her own consultancy company, eMSc, advising pharmaceutical companies on product development and quality.

Thomas Englese, MBA Chief Commercial Officer

Mr. Englese was promoted to Chief Commercial Officer of Tonix Pharmaceuticals in September 2026, having joined the company as Executive Vice President, Commercial Operations, in September 2024. He has over 20 years of experience in domestic and international commercial functions within biopharmaceutical companies, spanning therapeutic areas such as ADHD, pain management, and cardiology. Before Tonix, he served as Chief Commercial Officer at Tris Pharmaceuticals and Aziyo Biologics, where he was a key leader of the company's IPO team. Mr. Englese also held various positions at Mallinckrodt (formerly Ikaria Inc.) and Baxter Healthcare International, and worked at Pfizer and Wells Fargo earlier in his career.

Risk of Clinical Trial Failure and Inability to Obtain Regulatory Approval

As a clinical-stage biopharmaceutical company, Tonix Pharmaceuticals Holding Corp.'s success and future viability are heavily dependent on the successful progression of its numerous product candidates through pre-clinical studies, various phases of clinical trials, and ultimately, obtaining regulatory approvals from authorities such as the FDA. The drug development process is inherently uncertain, lengthy, and costly, with a high rate of failure at each stage. For example, TNX-102 SL, while in mid-Phase 3 development for fibromyalgia, still faces significant hurdles to achieve positive trial results and subsequent marketing authorization. Failures in clinical trials, delays in enrollment, unexpected adverse events, or an inability to demonstrate efficacy could prevent any of its immunology, rare disease, infectious disease, or CNS product candidates (such as TNX-1500, TNX-2900, TNX-801, or TNX-1900) from reaching the market, which would severely impact the company's ability to generate revenue.

Intellectual Property Protection Risk

Tonix Pharmaceuticals' business model relies significantly on its ability to discover, acquire, develop, and license therapeutics and diagnostics. A core asset for a biopharmaceutical company is its intellectual property, primarily patents and other forms of exclusivity, which protect its product candidates from generic competition. The company faces the ongoing risk that its patents may be challenged, invalidated, or circumvented by competitors. The inability to obtain, maintain, and enforce robust intellectual property protection for its product candidates could allow competitors to develop and market similar products, thereby diminishing the market potential and profitability of Tonix's pipeline assets.

Intense Competition in the Biopharmaceutical Industry

The biopharmaceutical industry is highly competitive, characterized by rapid technological change, intense research and development efforts, and significant financial resources invested by numerous companies. Tonix Pharmaceuticals operates in multiple therapeutic areas, including immunology, rare diseases, infectious diseases, and central nervous system disorders. The company faces competition from large pharmaceutical companies, other biotechnology firms, academic institutions, and government agencies that may have greater financial, technical, and human resources. Competitors may develop products that are more effective, safer, or less expensive than Tonix's candidates, or they may achieve earlier market introduction, which could negatively impact Tonix's market share and commercial prospects for drugs like TNX-1500 or TNX-102 SL.

The rapid and ongoing innovation by major pharmaceutical companies in developing highly effective mRNA vaccines (such as those from Pfizer-BioNTech and Moderna) and potent oral antiviral treatments (such as Paxlovid from Pfizer) for COVID-19 presents a clear emerging threat to Tonix Pharmaceuticals Holding's COVID-19 related pipeline assets (TNX-1840, TNX-1850, and TNX-3500). These established market leaders continue to evolve their platforms and products, setting a continuously high bar for efficacy, safety, and convenience, potentially making Tonix's later-stage candidates less competitive or even obsolete by the time they reach the market.

The addressable markets for Tonix Pharmaceuticals Holding's main product candidates are as follows:

• TNX-1500 (Prevention of allograft and xenograft rejection, and autoimmune diseases):
  • The global market for organ transplant rejection medication was valued at USD 5.5 billion in 2022 and is projected to reach USD 7.5 billion by 2032.
  • The global organ transplant immunosuppressant drugs market was estimated at USD 5.81 billion in 2025 and is predicted to grow to approximately USD 9.23 billion by 2035.
  • The global antibody-mediated rejection (AMR) prevention market is expected to reach USD 103.4 million in 2025 and expand to USD 613.7 million by 2035.
• TNX-2900 (Prader-Willi syndrome):
  • The global Prader-Willi syndrome market reached US$ 633.56 million in 2024 and is expected to reach US$ 1,078.80 million by 2033. Another estimate places the market in the 7MM (United States, EU4, United Kingdom, and Japan) at approximately USD 639.9 million in 2024, projected to reach USD 1,302.9 million by 2035.
• TNX-801 (Smallpox and monkeypox vaccine):
  • The global monkeypox vaccine and treatment market size was valued at USD 85.23 million in 2022 and is expected to reach USD 184.79 million by 2030. Other reports indicate the global market size was USD 117.2 million in 2025, expected to reach USD 495.3 million by 2034, and USD 111.66 million in 2025, predicted to reach USD 372.85 million by 2035.
• TNX-1840, TNX-1850, TNX-3500 (COVID-19 vaccines and acute COVID-19 treatment):
  • The global COVID-19 treatment market was valued at US$ 42.47 billion in 2025 and is expected to reach US$ 112.97 billion by 2034. The global COVID-19 infection market (including diagnostics, therapeutics, and preventive measures) was valued at USD 30.25 billion in 2025 and is expected to reach USD 79.28 billion by 2033.
• TNX-102 SL (Fibromyalgia and Long COVID):
  • Fibromyalgia: The global fibromyalgia treatment market size was valued at USD 2.75 billion in 2025 and is expected to reach USD 4.72 billion by 2033. North America accounted for approximately 45% of global revenue in 2025. Other sources indicate the global market was valued at $3.1 billion in 2022, projected to reach $4.6 billion by 2032, and reached $2.89 billion in 2025, projected to reach $3.67 billion by 2030.
  • Long COVID: The global Long COVID therapeutics market was worth USD 2.50 billion in 2025 and is projected to reach USD 4.52 billion by 2034. Long COVID affects 5 to 7 percent of U.S. adults, roughly 18 million people. Globally, over 65 million individuals are projected to have Long COVID.
• TNX-1900 (Migraine prevention):
  • The global anti-migraine drugs market is estimated to reach $33.6 billion by 2034. The migraine market across the seven major markets (7MM: US, France, Germany, Italy, Spain, UK, and Japan) is poised to grow from $9.2 billion in 2023 to $16.4 billion in 2033. North America led the global anti-migraine drugs market, accounting for over 47% share in 2024.
• TNX-1300 (Cocaine intoxication):
  • The global cocaine intoxication treatment market size is calculated at US$ 17.91 million in 2024 and is projected to reach around US$ 32.15 million by 2034. Another report estimates the total market size in the 7MM (United States, EU4, United Kingdom, and Japan) was approximately USD 126 million in 2023, with the US accounting for ~USD 84 million.

Tonix Pharmaceuticals Holding (symbol: TNXP) is expected to drive future revenue growth over the next 2-3 years through several key initiatives:

1. Commercialization and Expansion of TONMYA (TNX-102 SL) for Fibromyalgia: The primary driver of revenue growth is the commercial launch of TONMYA (cyclobenzaprine HCl sublingual tablets) for the management of fibromyalgia, which received FDA approval in August 2025 and began its commercial launch in late November 2025. This product represents the first new medicine approved for fibromyalgia in over 15 years. Tonix Pharmaceuticals reported initial net revenue of approximately $1.4 million from TONMYA between its launch and December 31, 2025, and subsequently $3.7 million in the first quarter of 2026 and $11 million in the second quarter of 2026, demonstrating significant quarter-over-quarter growth. The company is actively expanding its sales force (to 150 representatives by September 2026) and working to broaden payer coverage, with expectations to reach approximately 145 million lives (46% of the U.S. population) by January 2027, which is anticipated to accelerate sales.
2. Growth of Existing Migraine Product Franchise: Tonix Pharmaceuticals' current revenue streams from its migraine products, Zembrace SymTouch and Tosymra, are expected to continue to grow. For the full year 2025, net revenue from these products was approximately $11.7 million, an increase from $10.1 million in 2024. Notably, Tosymra is projected to benefit from preferred exclusive formulary placement covering approximately 16 million lives starting in January 2026, which is anticipated to boost its sales by reducing restrictions and co-pays.
3. Advancement of TNX-4800 for Lyme Disease Prevention: Tonix Pharmaceuticals acquired worldwide rights to TNX-4800, a monoclonal antibody for Lyme disease prevention, in September 2025. Given the absence of FDA-approved vaccines or prophylactics for Lyme disease, this candidate addresses a significant unmet medical need. The company plans to meet with the FDA in 2026 to discuss the design of a Phase 2/3 study and expects to initiate enrollment in an adaptive Phase 2 field study in the first quarter of 2027.
4. Advancement of TNX-1500 for Organ Transplant Rejection and Autoimmune Diseases: TNX-1500, a humanized monoclonal antibody targeting CD40-ligand, is Phase 2 ready. An investigator-initiated Phase 2 study with Massachusetts General Hospital for kidney transplant rejection prevention is expected to initiate in the second half of 2026, pending FDA clearance of the Investigational New Drug (IND) application. This program is also intended to target a broader autoimmune market over time.

Share Repurchases

• Tonix Pharmaceuticals' Board of Directors increased its share repurchase program, authorizing an additional $25.0 million on November 18, 2025, bringing the total authorized amount to $35 million.
• The company spent $13.8 million on share buybacks in fiscal year 2025.
• Prior to November 18, 2025, Tonix had repurchased 400,000 shares for approximately $5.95 million under the initial $10 million program.

Share Issuance

• Tonix Pharmaceuticals increased its At-The-Market (ATM) offering capacity from $150 million to $400 million on November 21, 2025. Under the previous prospectus, the company had sold 3,882,223 shares for an aggregate of $103.1 million.
• In December 2025, Tonix completed a registered direct offering with Point72, raising approximately $20 million through the sale of common stock and pre-funded warrants.
• Subsequent to June 30, 2026, the company raised an additional $3.7 million in proceeds through its At-the-Market facility.

Inbound Investments

• Point72 Asset Management made an investment of approximately $20 million in Tonix Pharmaceuticals in December 2025 as part of a registered direct offering.

Outbound Investments

• Tonix Pharmaceuticals Holding completed a Corporate Asset Purchase with Dr. Reddy's for Neurology Migraine Products on June 30, 2023.

Capital Expenditures

• Cash paid for capital expenditures for the full year ended December 31, 2025, was approximately $3.4 million, a significant increase from $0.1 million in 2024.
• For the six months ended June 30, 2025, cash used in investing activities, including the purchase of property and equipment, was $2.5 million.
• The company anticipates that its cash resources as of June 30, 2026, combined with recent equity offerings, will cover its planned operating and capital expenditure requirements into early the second quarter of 2027.